Nuveen’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Nuveen’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.7K	Buy	+100	New	+$9.39K	﹤0.01%	4557

Other funds holding PBE

HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.93B AUM 18.7% 1-Year Est. Return

YHB Investment Advisors West Hartford, Connecticut $1.59B AUM 21.04% 1-Year Est. Return

Institute for Wealth Management Denver, Colorado $1.13B AUM 31.46% 1-Year Est. Return

Penobscot Investment Management Boston, Massachusetts $1.44B AUM 23.59% 1-Year Est. Return

Massachusetts Wealth Management North Andover, Massachusetts $248M AUM 37.44% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.44B AUM 38.08% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return

Outlook Wealth Advisors Shenandoah, Texas $470M AUM 20.06% 1-Year Est. Return

Nuveen's PBE Position: Q3 2026 in Review

Nuveen opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q3 2026: 100 shares worth $9.7K. The stake represents ﹤0.01% of the portfolio and ranks #4557 among its holdings.

65 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

Nuveen held 100 shares of Invesco Biotechnology & Genome ETF worth $9.7K as of Q3 2026.
Invesco Biotechnology & Genome ETF was a new Nuveen position in Q3 2026.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4557 holding.
65 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.